|
Oct 11
|
High Growth Tech Stocks In France October 2024
|
|
Oct 10
|
Valneva Hosts Investor Day in New York City
|
|
Oct 9
|
Valneva SE (INRLF) (H1 2024) Earnings Call Highlights: Navigating Growth Amidst Revenue Challenges
|
|
Oct 9
|
Exclusive Networks And 2 High Growth Tech Stocks In France
|
|
Oct 8
|
Exploring Three High Growth Tech Stocks in France
|
|
Aug 6
|
VALNEVA - Declaration of shares and voting rights: July 31, 2024
|
|
Jul 26
|
Can Valneva (VALN) Climb 149.04% to Reach the Level Wall Street Analysts Expect?
|
|
Jun 24
|
Valneva Announces Health Canada Approval of the World’s First Chikungunya Vaccine, IXCHIQ®
|
|
May 31
|
Valneva Receives EMA’s Positive CHMP Opinion for its Chikungunya Vaccine
|
|
Jan 10
|
Valneva Vaccinates First Participant in Pediatric Trial of Single-Shot Chikungunya Vaccine
|
|
Jan 5
|
VALNEVA - Declaration of shares and voting rights: December 31, 2023
|
|
Jan 4
|
Valneva to Conduct Investor Meetings during the J.P. Morgan Healthcare Conference and Oddo BHF Forum
|
|
Dec 29
|
Valneva Provides Updated 2023 Financial Guidance
|
|
Dec 20
|
Valneva Shareholders Approve EGM Resolutions Including the Transition to a Board of Directors
|
|
Dec 6
|
VALNEVA Declaration of shares and voting rights - November 30, 2023
|
|
Dec 5
|
Pfizer, after delay, completes enrollment in Lyme vaccine trial
|
|
Dec 4
|
Pfizer and Valneva Complete Recruitment for Phase 3 VALOR Trial for Lyme Disease Vaccine Candidate, VLA15
|
|
Dec 4
|
Valneva Reports Positive 24-Month Antibody Persistence Data for its Single-Shot Chikungunya Vaccine IXCHIQ®
|
|
Nov 27
|
EMA Accepts Valneva’s Chikungunya Vaccine Marketing Authorization Application for Accelerated Assessment
|
|
Sep 7
|
UPDATE 1-Pfizer, Valneva say 'positive' result for Lyme disease vaccine candidate booster
|